Allay Therapeutics raised $57.5M in Series D financing, co-led by Lightstone Ventures and ClavystBio, to support its Phase 2b trial for post-surgical pain management.
Allay Therapeutics raised $57.5M in Series D financing, co-led by Lightstone Ventures and ClavystBio, to support its Phase 2b trial for post-surgical pain management.
06/05/25, 1:23 PM
Location
san joseMoney raised
$57.5 million
Industry
biotechnology
Round Type
series d
Investors
Hsbc Innovation Banking, Sg Innovate, Edbi, Ipd Capital, Brandon Capital, Vertex Ventures Healthcare, Vertex Growth, Arboretum Ventures, Nea, Clavyst Bio, Lightstone Ventures
Allay Therapeutics, a San Jose, CA-based biotech company, raised $57.5M in Series D financing. The company will use the funds to support its Phase 2b registration trial for ATX101 following TKA surgery. Lightstone Ventures and ClavystBio co-led the round, with participation from NEA and others. Additional venture debt financing was provided by IPD Capital and others.
Company Info
Location
2720 zanker road
san jose, california, united states
Additional Info
Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians.
We believe an era of stalled innovation for pain management is over. From San Francisco to Singapore, our team has a passion for solving medical challenges that could benefit millions. We pursue our mission with the energy of a dynamic, global team of entrepreneurs, scientists, clinicians and innovators.